David Yomtoob, MD
Ophthalmology · Orange, CANPI 1841487030
Payments from drug & device makers
Across 336 payments — averaging $187.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$30K
- Glaukos Corporation$23K
- AbbVie$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Sight Sciences, Inc.$671
- Aerie Pharmaceuticals, Inc.$569
- plus $4K from 22 others
What the payments were for
- Consulting fees$4,33530%
- Speaking & faculty fees$3,02621%
- Food & beverage$6,95449%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 14 | $30,152 |
| Glaukos Corporation | 47 | $23,452 |
| AbbVie(2 entities) | 44 | $2,688 |
| Johnson & Johnson Surgical Vision, Inc. | 24 | $2,020 |
| Sight Sciences, Inc. | 26 | $671 |
| Aerie Pharmaceuticals, Inc. | 36 | $569 |
| Alcon | 27 | $544 |
| NEW World Medical,inc. | 14 | $459 |
| Sun Pharmaceutical Industries Inc. | 18 | $337 |
| Bausch & Lomb Americas Inc. | 12 | $257 |
| Nova Eye, Inc. | 2 | $230 |
| Oyster Point Pharma, Inc. | 7 | $214 |
| Dompe US, Inc. | 8 | $195 |
| Amgen(2 entities) | 6 | $171 |
| Thea Pharma Inc. | 7 | $155 |
| Shire North American Group Inc | 9 | $153 |
| Carl Zeiss Meditec USA, Inc. | 2 | $151 |
| Tarsus Pharmaceuticals, Inc. | 4 | $146 |
| Novartis | 7 | $146 |
| Eyevance Pharmaceuticals LLC | 7 | $118 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $91 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Akorn, Inc. | 2 | $47 |
| Akorn Operating Company LLC | 2 | $39 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Oasis Medical, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$1,650
- COMBIGAN$1,650
- ALPHAGAN P$1,650
- Tecnis Simplicity$1,560
- iStent Trabecular Micro-Bypass Stent System$1,500
- iDose$1,125
- OMNI(R) SURGICAL SYSTEM (US)$262
- SION SURGICAL INSTRUMENT$140
- DURYSTA$125
- FORUM$122
- PHOTREXA CROSS-LINKING KIT$113
How this compares
$63,151 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 184 | $110,607 |
| XiidraLifitegrast | 78 | $110,120 |
| RestasisCyclosporine | 66 | $92,992 |
| RhopressaNetarsudil Mesylate | 135 | $80,567 |
| Alphagan PBrimonidine Tartrate | 125 | $76,768 |
| VyzultaLatanoprostene Bunod | 36 | $26,851 |
| Travoprost | 142 | $26,453 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 54 | $25,492 |
| XdemvyLotilaner | 14 | $25,271 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 92 | $21,970 |
| TyrvayaVarenicline Tartrate | 22 | $21,905 |
| Travatan ZTravoprost | 34 | $18,802 |
| CequaCyclosporine | 20 | $18,780 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $17,899 |
| MieboPerfluorohexyloctane/Pf | 22 | $17,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $2,688 | $295,152420 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $257 | $154,813136 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $569 | $98,466155 claims |
| AlconSimbrinza, Azopt | $544 | $34,11671 claims |
| NovartisTravatan Z, Ilevro | $146 | $30,36365 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $146 | $25,27114 claims |
| Sun Pharmaceutical Industries Inc.Cequa, Bromsite | $337 | $22,26134 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $214 | $21,90522 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $91 | $15,36047 claims |
| Thea Pharma Inc.Iyuzeh | $155 | $13,61631 claims |
| Akorn, Inc.Zioptan | $47 | $7,68016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Orange
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.